Abstract
* Bevacizumab (Avastin) is now approved to treat persistent, recurrent, or metastatic cervical cancer when given with one of two other approved drug therapies, paclitaxel and cisplatin or paclitaxel and topotecan.
* The most common adverse effects noted in the phase 3 study of bevacizumab used to treat ovarian cancer were fatigue, decreased appetite, hypertension, hyperglycemia, hypomagnesemia, urinary tract infection, headache, and weight loss. Severe adverse effects are possible.